Colgate Total, American Diabetes Association partner to educate on gum health
BY Ryan Chavis
NEW YORK — In recognition of American Diabetes Month, Colgate Total on Tuesday announced the "Small Steps Make A Big Difference" campaign to help raise awareness surrounding the relationship between oral health and diabetes.
Gum disease and diabetes are both critical issues in the United States, the brand said. More than 75% of adults experience some form of gum disease and nearly 1-in-10 American adults have diabetes. The prevalence of diabetes is even higher among certain populations: 12.8% of U.S. Hispanic and 13.2% of African-American adults live with diabetes, compared to 7.6% of non-Hispanic whites, according to statistics from the Centers for Disease Control and Prevention.
The CDC also notes that people living with diabetes are twice as likely to develop gum disease; diabetics are more prone to infections and less able to fight germs that invade gums.
To better assist people with diabetes and their families with the resources they need to maintain a healthy smile, Colgate Total has partnered with "Small Steps Make A Big Difference" experts. Experts include:
- Natalie Strand, M.D. — CMO Freedom Pain Hospital, VP Integrative Medical Services and co-author of upcoming book "A Woman’s Guide to Diabetes." Twitter: @DrNatStrand;
- Marjorie Cypress, PhD, C-ANP, CDE — President, health care and education of the American Diabetes Association;
- Karent Sierra, DDS — Miami-based bilingual dentist and founder of Sharing Smiles Foundation. Twitter: @KarentSierra; and
- Catrise Austin, DDS — Celebrity cosmetic dentist and author of "Winning the Fight Against Diabetes: The secrets to living longer and healthier with a smile!" Twitter: @DrCatriseAustin
“People living with diabetes already know that small steps — like managing your stress to help keep your appetite in check — can make a big difference in personal health over time, and the same could be said of oral health,” said Natalie Strand, M.D. “A small, easy step people can do is brush twice a day with Colgate Total, which can help improve gum health in as little as four weeks”.
In tandem with the American Diabetes Association, Colgate Total launched a survey of 1,555 members of the Association to better understand how respondents understand oral health. The survey showed that:
- Thirty-eight percent of people don't agree or don't know that oral health problems can be a complication of poorly managed diabetes;
- More than 36% of people living with diabetes or prediabetes currently deal with oral health problems, which makes it the third most-common medical condition for those surveyed with diabetes (or prediabetes); and
- More than 90% of people surveyed have experienced at least oral health issue despite the fact that nearly 69% of those surveyed report making at least one trip to the dentist every year.
“As the only toothpaste FDA-approved and American Dental Association-accepted to help prevent gingivitis, which is the most common form of gum disease, Colgate Total is a good choice for people with diabetes,” said Dr. Foti Panagakos, global director of scientific affairs and research at Colgate-Palmolive. “Throughout our long-standing, strategic partnership with the American Diabetes Association, we’ve focused joint efforts on creating an ongoing dialogue and providing tools to help people living with diabetes better manage their oral health.”
For more information on oral health and diabetes, as well as ways to improve gum health, visit OralHealthAndDiabetes.com.
CVS Health focuses on digital to improve pharmacy, front-end experience
WOONSOCKET, R.I. — Across the front-end, CVS Health is in the midst of enhancing its digital capabilities, Helena Foulkes, EVP CVS Health and president CVS/pharmacy, told analysts Tuesday morning during the company's third-quarter conference call. In addition, the company provided insight into the impact of its exit from the tobacco business during the call.
CVS Health is focused on its omnichannel experience with their core pharmacy customers. "We're thinking very holistically from the customer's perspective just in terms of the experience and how we want to use our assets," Foulkes told analysts. "When the customer thinks about CVS, she's thinking first and foremost about pharmacy, and health and beauty is a really important part of that," she said. "We're spending a lot more time … thinking about the connection between stores and digital and really enhancing the experience for our customers around digital. I'm excited about the work we've got going on there. It's again focused on the pharmacy, but the front store is an important part of that as well."
Regarding CVS Health's decision to no longer sell tobacco products, there is one thing that decision is not doing. It's not hurting their pharmacy business. "As expected, we have seen no discernable impact on our pharmacy business," Larry Merlo, CVS Health president and CEO said.
Quite to the contrary, CVS Health's pharmacy and health-and-wellness segments are performing well.
"Continuing the strong trend that we saw in the second quarter, we once again gained pharmacy share in Q3," he said. Year-over-year our pharmacy marketshare increased about 40 basis points on a 30 day equivalent basis. Pharmacy same-store sales increased 4.8% vs. the same quarter last year, while pharmacy same-store scripts increased 5.1%, again on a 30 day equivalent basis." That growth includes a collective 380 basis point negative impact from recent generic introductions and the implementation of Specialty Connect, Merlo said, which transfers specialty prescriptions from CVS' retail segment to its PBM segment.
And though the tobacco exit has contributed to a decline of 4.5% in front-end comparable sales, CVS Health's front-end is on an upward trajectory. Adjusting for the tobacco impact, comps would have been approximately 480 basis points higher. CVS Health's front-end margins are up, Merlo noted, and less than one-third can be attributed to the absence of low-margin tobacco products. That means two-thirds of the improvement are attributal to responsible promotional investments and driving store brand.
Speaking of which, CVS' store brand penetration is up 210 basis points to 20.1% of front-store sales, with only half of the improvement related to the tobacco exit (CVS carried no private label tobacco products).
Rogaine launches topical foam for women
BY Ryan Chavis
SKILLMAN, N.J. — Rogaine brand on Tuesday announced the launch of Women's Rogaine 5% Minoxidil topical aerosol, the first and only once-daily treatment approved by the Food and Drug Administration for the treatment of female pattern hair loss, according to the brand. Minoxidil is the only topical ingredient FDA-approved to help with hair regrowth.
The treatment works by penetrating the scalp to reactivate hair follicles and stimulate hair regrowth. It's a ideal solution for women looking for a proven solution rather than a quick cosmetic fix, the brand said.
“Women with female pattern hair loss should not feel alone. Treatment options have come a long way, and the recent FDA-approval of Women’s Rogaine 5% Minoxidil topical aerosol is a major advancement in the category," said New York City dermatologist Dr. Doris Day. "Unlike cosmetic thickeners, which coat the hair and temporarily mask the issue, this innovative product when used once a day — every day —actually helps regrow hair. And, its unique, enhanced bio-delivery system is designed to break down with body heat to deposit actives on the scalp without residue to make styling that much easier.”
Women's Rogaine can be applied to dry or towel-dried hair and may be followed with styling products of the consumer's choice. The product also can be used on colored or chemically treated hair, but shouldn't be used on the same day of any chemical treatment to the hair; continued use of Women's Rogaine is required to maintain results.
Women's Rogaine is available without a prescription for a suggested retail price of $29.99 for a two-month supply and $49.99 for a four-month supply.
Loading Post Please Wait...